For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Sponsored Links
Main Menu
Community
Treatment
Understand
- Where to Start
- What is Lymphoma?
- The Lymphatic System
- Lymphoma Symptoms
- Lymphoma Causes
- Lymphoma Prognosis
- Refractory/Relapsed Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Surviving Lymphoma
Lymphoma and Pets
More
Pixantrone shows promise for patients with relapsed/refractory NHL
-
Call (877) 399-6937 or click here to learn more about Cancer Treatment options.
Dr. Richard Van der Jagt of Ottawa General Hospital presented results from phase II and phase III clinical studies of pixantrone at this weekend's Lymphoma and Myeloma 2009 Conference (October 22-24 2009).
PIXANTRONE
Drug class: Anthracenediones. The only other drug in this class is mitoxantrone. In fact, pixantrone is a less-toxic analogue of mitoxantrone.
Classification: Type II topoisomerase inhibitor. This means it interferes with enzymes that control DNA structure, causing breaks in the DNA and leading to cell death. Etopiside and doxorubicin are topoisomerase II inhibitors.
Current status: FDA fast track; could be available in 2010
PERFORMANCE IN CLINICAL TRIALS
Phase II and phase III clinical studies showed that pixantrone performed pretty well when used in combination with other drugs:
Patients with: Relapsed/refractory indolent NHL
Combination: FPD-R regimen (fludarabine, pixantrone, dexamethasone, rituximab)
Complete remission: 70%
Patients with: Relapsed/refractory aggressive NHL where CHOP failed
Combination: CPOP regimen (cyclophosphamide, pixantrone, vincristine, prednisone)
Complete remission: 47%
Patients with: Relapsed/refractory indolent NHL
Combination: Pixantrone + rituximab
Complete remission: 35%
COMMENTARY
"The results from the pixantrone clinical trials are impressive and indicate the potential for this drug to meet a significant unmet medical need in patients with relapsed or refractory NHL," said Dr. Gary Schiller of the UCLA School of Medicine. "These patients have few options and the availability of an effective treatment would be well received."
-
Call (877) 399-6937 or click here to learn more about Cancer Treatment options.
Support Groups
Find a Treatment Facility Near You
Click on a state below to find Lymphoma treatment options that could be right for you.
Select a State Below
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
Sponsored Links
LymphomaInfo Social
SupportGroups.com
SupportGroups.com provides a support network for those dealing with cancer and other life's challenges. Click on the following links to get the support in a confidential, caring environment.
Follow LymphomaInfo.net on:
Facebook:
Twitter: